Thyrocare Technologies Ltd

Thyrocare Technologies Ltd

Docon Technologies Private Limited, a wholly-owned subsidiary of API Holdings Limited and a promoter of Thyrocare Technologies Limited, has sold 1,57,69,696 equity shares of Thyrocare, representing approximately 9.9% of the total paid-up share capital, reducing the promoter shareholding from 60.92% to 51.02%.

Thyrocare Technologies Ltd

Thyrocare Technologies Ltd's promoter, Docon Technologies Private Ltd, has released a pledge on 1,75,00,000 equity shares of the company, held by Docon, which were pledged in favour of Catalyst Trusteeship Limited, acting as the Debenture Trustee.

Thyrocare Technologies Ltd

Thyrocare Technologies Ltd has received a disclosure from its promoter, Docon Technologies Private Limited, stating that it has sold 1,57,69,696 equity shares of the company through market trades, representing approximately 9.90% of the total paid-up equity share capital. This has reduced the promoter's shareholding from 60.92% to 51.02%.

Thyrocare Technologies Ltd

Thyrocare Technologies Ltd has received a communication from its promoter, Docon Technologies Private Limited, regarding the release of a pledge on 1,75,00,000 equity shares of the company. The pledge was released by Catalyst Trusteeship Limited on August 11, 2026, and the promoter has submitted the required disclosures under SEBI regulations.

Thyrocare Technologies Ltd

Thyrocare Technologies Ltd has released the transcript of its Q1 FY27 earnings conference call, which was held on July 23, 2026. The company's management discussed its quarterly highlights, including its growth in Africa and its recognition as India's most trusted customer-focused diagnostic brand.

Thyrocare Technologies Ltd

Thyrocare Technologies Ltd has resubmitted its unaudited financial results for the quarter ended June 30, 2026, in machine-readable format as per NSE Circular No. NSE/CML/2018/02 dated January 16, 2018.

Thyrocare Technologies Ltd

Thyrocare Technologies Ltd has published unaudited financial results for the quarter ended June 30, 2026, in accordance with Regulation 30 and 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Thyrocare Technologies Ltd

Thyrocare Technologies Ltd has made available the audio recording of its earnings conference call for the quarter ended June 30, 2026, on its website at https://investor.thyrocare.com/financials/quarterly-financial-results/. The transcript will be shared shortly.

Thyrocare Technologies Ltd

Thyrocare Technologies Ltd has announced the in-principle approval of its Board of Directors for the evaluation of a proposed demerger of its wholly-owned subsidiary Nueclear Healthcare Limited's radiology business.

Thyrocare Technologies Ltd

Thyrocare Technologies Ltd has announced the re-appointment of Ernst & Young LLP as its Internal Auditor for the Financial Year 2026-27. The company has also approved its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026.

Thyrocare Technologies Ltd

Thyrocare Technologies Ltd has released its unaudited financial results for Q1 FY27, showing a 24% YoY revenue growth and 34% YoY PAT growth. The company has also launched new laboratories, expanded its capabilities, and strengthened its relationships with channel partners.

Thyrocare Technologies Ltd

Thyrocare Technologies Ltd reported Q1FY27 results with revenue of INR 240.02 Cr, a 24% YoY growth, driven by a 26% increase in the Pathology segment. EBITDA grew by 34% YoY to INR 77.27 Cr, and PAT grew by 34% YoY to INR 51.33 Cr. The company expanded into Specialty Diagnostics, marking the next phase of its growth journey.

Thyrocare Technologies Ltd

Thyrocare Technologies Ltd has announced its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, along with the Limited Review Report. The Board has approved the results, and the company has also re-appointed Ernst & Young LLP as its Internal Auditor for the Financial Year 2026-27.

Thyrocare Technologies Ltd

Thyrocare Technologies Ltd announced the outcome of its Board Meeting held on July 23, 2026, where it approved unaudited financial results for the quarter ended June 30, 2026, and re-appointed Ernst & Young LLP as Internal Auditor for the Financial Year 2026-27.